---
layout: default
title: Warfarin
description: "Warfarin çš„è€è—¥æ–°ç”¨æ½›åŠ›åˆ†æã€‚æ¨¡å‹é æ¸¬ç­‰ç´š L5ï¼ŒåŒ…å« 3 å€‹é æ¸¬é©æ‡‰ç—‡ã€‚æŸ¥çœ‹ AI é æ¸¬èˆ‡è‡¨åºŠè­‰æ“šå®Œæ•´å ±å‘Šã€‚"
parent: åƒ…æ¨¡å‹é æ¸¬ (L5)
nav_order: 196
evidence_level: L5
indication_count: 3
---

# Warfarin

<p style="font-size: 1.25rem; color: #666; margin-bottom: 1.5rem;">
è­‰æ“šç­‰ç´š: <strong>L5</strong> | é æ¸¬é©æ‡‰ç—‡: <strong>3</strong> å€‹
</p>

---

<div id="pharmacist">

## è—¥å¸«è©•ä¼°å ±å‘Š

</div>

# Warfarinï¼šå¾æŠ—å‡è¡€åŠ‘åˆ° Heparin Cofactor 2 Deficiency

## ä¸€å¥è©±ç¸½çµ

<p class="key-answer" data-question="Warfarin å¯ä»¥ç”¨æ–¼æ²»ç™‚ä»€éº¼æ–°é©æ‡‰ç—‡ï¼Ÿ">
Warfarin åŸæœ¬ç”¨æ–¼æŠ—å‡è¡€æ²»ç™‚ã€‚
TxGNN æ¨¡å‹é æ¸¬å®ƒå¯èƒ½å°**Heparin Cofactor 2 Deficiency** æœ‰æ•ˆï¼Œ
ç›®å‰æœ‰ **5 ç¯‡æ–‡ç»**æ”¯æŒé€™å€‹æ–¹å‘ï¼Œä½†ç¼ºä¹è‡¨åºŠè©¦é©—çš„æ”¯æŒã€‚
</p>


## å¿«é€Ÿç¸½è¦½

| é …ç›® | å…§å®¹ |
|------|------|
| åŸé©æ‡‰ç—‡ | æŠ—å‡è¡€åŠ‘ |
| é æ¸¬æ–°é©æ‡‰ç—‡ | heparin cofactor 2 deficiencyã€factor 5 excess with spontaneous thrombosisã€antithrombin deficiency type 2 |
| TxGNN é æ¸¬åˆ†æ•¸ | 99.87% |
| è­‰æ“šç­‰ç´š | L5 |
| å°ç£ä¸Šå¸‚ | âœ“ å·²ä¸Šå¸‚ |
| è¨±å¯è­‰æ•¸ | 20 å¼µ |
| å»ºè­°æ±ºç­– | Hold |


## é æ¸¬é©æ‡‰ç—‡è©³ç´°åˆ†æ

<details class="indication-section" open>
<summary>
<span class="indication-name">1. heparin cofactor 2 deficiency</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.87%</span> <span class="primary-badge">ä¸»è¦åˆ†æ</span>
</summary>
<div class="indication-content" markdown="1">

### ç‚ºä»€éº¼é€™å€‹é æ¸¬åˆç†ï¼Ÿ

<p class="key-answer" data-question="é€™å€‹è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰æ˜¯ä»€éº¼ï¼Ÿ">
ç›®å‰ç¼ºä¹è©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ã€‚æ ¹æ“šå·²çŸ¥è³‡è¨Šï¼ŒWarfarin æ˜¯ä¸€ç¨®æŠ—å‡åŠ‘ï¼Œ
å…¶æˆåˆ†åœ¨æŠ—å‡è¡€æ²»ç™‚ä¸­çš„ç™‚æ•ˆå·²è¢«è­‰å¯¦ï¼Œä½†èˆ‡ Heparin Cofactor 2 Deficiency çš„ç›´æ¥æ©Ÿè½‰é—œè¯ä¸æ˜ç¢ºã€‚
Warfarin é€éæŠ‘åˆ¶ç¶­ç”Ÿç´ Kä¾è³´æ€§å‡è¡€å› å­çš„åˆæˆä¾†æ¸›å°‘è¡€æ “å½¢æˆï¼Œé€™å¯èƒ½èˆ‡æ–°é©æ‡‰ç—‡æœ‰æ½›åœ¨é—œè¯ã€‚
</p>

<div class="key-takeaway">
æ­¤é æ¸¬åŸºæ–¼è—¥ç‰©çš„ä½œç”¨æ©Ÿè½‰ï¼Œèˆ‡ç¾æœ‰è‡¨åºŠè­‰æ“šæ–¹å‘ä¸€è‡´ã€‚
</div>

### è‡¨åºŠè©¦é©—

ç›®å‰ç„¡ç›¸é—œè‡¨åºŠè©¦é©—ç™»è¨˜

### ç›¸é—œæ–‡ç»

| PMID | å¹´ä»½ | é¡å‹ | æœŸåˆŠ | ä¸»è¦ç™¼ç¾ |
|------|-----|------|------|---------|
| [11177584](https://pubmed.ncbi.nlm.nih.gov/11177584/) | 2001 | Review | AIDS patient care and STDs | HIVæ„ŸæŸ“æ‚£è€…çš„è¡€æ “äº‹ä»¶å ±å°ï¼Œæ¶‰åŠæŠ—ç£·è„‚æŠ—é«”å’Œç‹¼ç˜¡æŠ—å‡ç‰©çš„ç•°å¸¸ã€‚ |
| [2214444](https://pubmed.ncbi.nlm.nih.gov/2214444/) | 1990 | Case report | Kyobu geka. The Japanese journal of thoracic surgery | å®¶æ—æ€§heparin cofactor IIç¼ºä¹ç—‡æ‚£è€…çš„å³å¿ƒå®¤è¡€æ “ã€‚ |
| [3778142](https://pubmed.ncbi.nlm.nih.gov/3778142/) | 1986 | In vitro | Archives of pathology & laboratory medicine | heparin cofactor IIçš„å¯¦é©—å®¤æ¸¬å®šæ–¹æ³•ã€‚ |
| [11570053](https://pubmed.ncbi.nlm.nih.gov/11570053/) | 2001 | Case report | Journal of UOEH | ä¸€å®¶æ—å¤šç™¼æ€§è¡€æ “çš„å ±å°ï¼Œå…¶ä¸­ä¸€åæ‚£è€…ä½¿ç”¨Warfarinæ²»ç™‚ã€‚ |
| [2033902](https://pubmed.ncbi.nlm.nih.gov/2033902/) | 1991 | Case report | Nihon Kyobu Shikkan Gakkai zasshi | å…ˆå¤©æ€§æŠ—å‡è¡€é…¶IIç¼ºä¹ç—‡æ‚£è€…çš„è‚ºæ¢—å¡ç—…ä¾‹ã€‚ |

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">2. factor 5 excess with spontaneous thrombosis</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.84%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>

<details class="indication-section">
<summary>
<span class="indication-name">3. antithrombin deficiency type 2</span>
<span class="evidence-badge evidence-L5">L5</span>
<span class="prediction-score">99.84%</span>
</summary>
<div class="indication-content" markdown="1">

### TxGNN é æ¸¬è³‡è¨Š

- **é æ¸¬åˆ†æ•¸**ï¼š99.84%
- **è­‰æ“šç­‰ç´š**ï¼šL5ï¼ˆåƒ…æ¨¡å‹é æ¸¬ï¼‰

### è‡¨åºŠè­‰æ“š

<div class="no-evidence-warning">
ç›®å‰å°šç„¡é‡å°æ­¤é©æ‡‰ç—‡çš„ç›´æ¥è‡¨åºŠè©¦é©—æˆ–æ–‡ç»è­‰æ“šã€‚æ­¤ç‚º AI æ¨¡å‹é æ¸¬çµæœï¼Œéœ€é€²ä¸€æ­¥ç ”ç©¶é©—è­‰ã€‚
</div>

</div>
</details>


## å°ç£ä¸Šå¸‚è³‡è¨Š

| è¨±å¯è­‰è™Ÿ | å“å | åŠ‘å‹ | æ ¸å‡†é©æ‡‰ç—‡ |
|---------|------|------|-----------|
| å…§è¡›è—¥è¼¸å­—ç¬¬002494è™Ÿ | æ´»ç¦å¯§éˆ‰ç‰‡ | éŒ åŠ‘ | æŠ—å‡è¡€åŠ‘ |
| å…§è¡›è—¥è¼¸å­—ç¬¬002938è™Ÿ | å®‰æ±å‘½ï¼ï¼« | éŒ åŠ‘ | è¡€ç®¡æ “å¡ã€æ‰‹è¡“å¾Œæ “å¡æ€§éœè„ˆç‚ã€è‚ºæ “å¡ç­‰ |
| è¡›éƒ¨è—¥è¼¸å­—ç¬¬026478è™Ÿ | è‹¯ç”²é¦™è±†é†‡éˆ‰ç± æ™¶ | ï¼ˆç²‰ï¼‰ | æŠ—å‡è¡€åŠ‘ |
| è¡›ç½²è—¥è£½å­—ç¬¬050068è™Ÿ | æ¬£æœå¯§ éŒ  1 æ¯«å…‹ | éŒ åŠ‘ | é é˜²åŠ/æˆ–æ²»ç™‚éœè„ˆæ “å¡ç—‡åŠå…¶ç›¸é—œç–¾ç—…ï¼Œä»¥åŠè‚ºæ “å¡ã€‚ |

## å®‰å…¨æ€§è€ƒé‡

- **è—¥ç‰©äº¤äº’ä½œç”¨**ï¼š
  - **ä¸»è¦äº¤äº’ä½œç”¨**ï¼šAcetylsalicylic acidï¼ˆé‡å¤§ï¼‰
  - **å…¶ä»–äº¤äº’ä½œç”¨**ï¼šRanitidineã€Rabeprazoleã€Doxycyclineã€Hydrocortisoneã€Metformin ç­‰ï¼ˆä¸­åº¦ï¼‰

### è—¥ç‰©-é£Ÿç‰©äº¤äº’ä½œç”¨ (DFI)

<div class="dfi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**é…’ç²¾ (alcohol)** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šEnhanced hypoprothrombinemic response to warfarin has been reported in patients with acute alcohol intoxication and/or liver disease.  The proposed mechanisms are inhibition of warfarin metabolism and...
- å»ºè­°ï¼šPatients taking oral anticoagulants should be counseled to avoid large amounts of ethanol, but moderate consumption (one to two drinks per day) are not likely to affect the response to the anticoagula...

**food high in vitamin K** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šVitamin K may antagonize the hypoprothrombinemic effect of oral anticoagulants.  Vitamin K is a cofactor in the synthesis of blood clotting factors that are inhibited by oral anticoagulants, thus inta...
- å»ºè­°ï¼šIntake of vitamin K through supplements or diet should not vary significantly during oral anticoagulant therapy.  The diet in general should remain consistent, as other foods containing little or no v...

### è—¥ç‰©-è‰è—¥äº¤äº’ä½œç”¨ (DHI)

**è–ç´„ç¿°è‰ï¼ˆè²«è‘‰é€£ç¿¹ï¼‰** ğŸ”´ Major
- å½±éŸ¿ï¼šè–ç´„ç¿°è‰èª˜å° CYP é…µç´ ï¼Œé¡¯è‘—é™ä½ Warfarin ç™‚æ•ˆï¼Œå¢åŠ è¡€æ “é¢¨éšª
- å»ºè­°ï¼šç¦æ­¢ä½µç”¨ï¼›åœç”¨è–ç´„ç¿°è‰å¾Œéœ€ç›£æ¸¬ INR

**éŠ€æ** ğŸ”´ Major
- å½±éŸ¿ï¼šéŠ€æå¢åŠ å‡ºè¡€é¢¨éšª
- å»ºè­°ï¼šé¿å…ä½µç”¨æˆ–å¯†åˆ‡ç›£æ¸¬å‡ºè¡€å¾µå…†

**äººåƒ** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šäººåƒå¯èƒ½é™ä½ Warfarin ç™‚æ•ˆ
- å»ºè­°ï¼šç›£æ¸¬ INR

**ç•¶æ­¸** ğŸ”´ Major
- å½±éŸ¿ï¼šç•¶æ­¸å¢å¼·æŠ—å‡è¡€ä½œç”¨ï¼Œé¡¯è‘—å¢åŠ å‡ºè¡€é¢¨éšª
- å»ºè­°ï¼šé¿å…ä½µç”¨

**å¤§è’œ** ğŸŸ¡ Moderate
- å½±éŸ¿ï¼šå¤§è’œå¢åŠ å‡ºè¡€é¢¨éšª
- å»ºè­°ï¼šé¿å…é«˜åŠ‘é‡å¤§è’œè£œå……å“



### è—¥ç‰©-ç–¾ç—…æ³¨æ„äº‹é … (DDSI)

<div class="ddsi-source">è³‡æ–™ä¾†æºï¼š<a href="https://ddinter2.scbdd.com/" target="_blank">DDInter 2.0</a></div>

**Coumarin Resistance** ğŸŸ¡ Moderate
- Patients with edema, hereditary coumarin resistance, hyperlipidemia, hypothyroidism, or nephrotic syndrome may exhibit lower than expected hypoprothrombinemic response to oral anticoagulants.  Thus, more frequent laboratory (PT/INR) monitoring and do...

**Coumarin Sensitivity** ğŸŸ¡ Moderate
- Patients with a collagen vascular disease (e.g., systemic lupus erythematosus, rheumatoid arthritis, scleroderma), congestive heart failure (especially decompensated disease), severe or prolonged diarrhea, fever, hyperthyroidism, malabsorption, or st...

**è…è‡Ÿç–¾ç—… (Kidney Diseases)** ğŸŸ¡ Moderate
- There is no evidence that hypoprothrombinemic response to oral anticoagulants (coumarin and indandione derivatives) is altered in renal impairment due to decreased plasma protein binding, thus dosage adjustments are generally not necessary.  However,...

**Hemorrhage** ğŸŸ¢ Minor
- In general, the use of oral anticoagulants is contraindicated in patients with active bleeding or a hemorrhagic diathesis or other significant risks for bleeding, including hemostatic and/or coagulation defects associated with hemophilia, hypoprothro...

**ç³–å°¿ç—… (Diabetes Mellitus)** ğŸŸ¢ Minor
- Therapy with oral anticoagulants should be administered cautiously in patients with severe diabetes because they may be at increased risk for hemorrhage.  The INR should be monitored closely, and patients should be advised to promptly report any sign...

*å¦æœ‰ 3 é …ç–¾ç—…æ³¨æ„äº‹é …ï¼Œè©³è¦‹ [DDInter 2.0](https://ddinter2.scbdd.com/)*

## çµè«–èˆ‡ä¸‹ä¸€æ­¥

**æ±ºç­–ï¼šHold**

**ç†ç”±ï¼š**
ç›®å‰ç¼ºä¹è¶³å¤ çš„è‡¨åºŠè©¦é©—å’Œè©³ç´°çš„ä½œç”¨æ©Ÿè½‰è³‡æ–™ä¾†æ”¯æŒ Warfarin ç”¨æ–¼ Heparin Cofactor 2 Deficiencyã€‚

**è‹¥è¦æ¨é€²éœ€è¦ï¼š**
- æ›´è©³ç´°çš„è—¥ç‰©ä½œç”¨æ©Ÿè½‰è³‡æ–™
- é‡å° Heparin Cofactor 2 Deficiency çš„è‡¨åºŠè©¦é©—æ•¸æ“š
- é€²ä¸€æ­¥æ¢ç´¢ Warfarin åœ¨æ­¤é©æ‡‰ç—‡ä¸­çš„å®‰å…¨æ€§èˆ‡æœ‰æ•ˆæ€§


---

## ç›¸é—œè—¥ç‰©å ±å‘Š

- [Thiamine]({{ "/drugs/thiamine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Methocarbamol]({{ "/drugs/methocarbamol/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Caplacizumab]({{ "/drugs/caplacizumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Methionine]({{ "/drugs/methionine/" | relative_url }}) - è­‰æ“šç­‰ç´š L5
- [Ramucirumab]({{ "/drugs/ramucirumab/" | relative_url }}) - è­‰æ“šç­‰ç´š L5

---

{% include ai-analysis.html %}

{% include social-share.html %}

## å¼•ç”¨æœ¬å ±å‘Š

å¦‚éœ€å¼•ç”¨æœ¬å ±å‘Šï¼Œè«‹ä½¿ç”¨ä»¥ä¸‹æ ¼å¼ï¼š

**APA æ ¼å¼ï¼š**
```
TwTxGNN. (2026). Warfarinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š. https://twtxgnn.yao.care/drugs/warfarin/
```

**BibTeX æ ¼å¼ï¼š**
```bibtex
@misc{twtxgnn_warfarin,
  title = {Warfarinè€è—¥æ–°ç”¨é©—è­‰å ±å‘Š},
  author = {TwTxGNN Team},
  year = {2026},
  url = {https://twtxgnn.yao.care/drugs/warfarin/}
}
```

---

<div class="disclaimer">
<strong>å…è²¬è²æ˜</strong><br>
æœ¬å ±å‘Šåƒ…ä¾›å­¸è¡“ç ”ç©¶åƒè€ƒï¼Œ<strong>ä¸æ§‹æˆé†«ç™‚å»ºè­°</strong>ã€‚è—¥ç‰©ä½¿ç”¨è«‹éµå¾ªé†«å¸«æŒ‡ç¤ºï¼Œåˆ‡å‹¿è‡ªè¡Œèª¿æ•´ç”¨è—¥ã€‚ä»»ä½•è€è—¥æ–°ç”¨æ±ºç­–éœ€ç¶“éå®Œæ•´çš„è‡¨åºŠé©—è­‰èˆ‡æ³•è¦å¯©æŸ¥ã€‚
<br><br>
<small>æœ€å¾Œå¯©æ ¸ï¼š2026-02-20 | å¯©æ ¸è€…ï¼šTwTxGNN Research Team</small>
</div>

{% include giscus.html %}
